Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Dec 12:19:2729-2737.
doi: 10.2147/COPD.S478349. eCollection 2024.

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Shigeo Muro  1 , Munehiro Seki  2 , John R Hurst  3 , David Petullo  4 , Jonathan Marshall  5 , Karin Bowen  4 , Patrick F Darken  4 , Elizabeth A Duncan  6 , Ayman Megally  4 , Mehul Patel  5
Affiliations
Clinical Trial

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Shigeo Muro et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: We evaluated the inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus dual LAMA/LABA and ICS/LABA therapies in patients with chronic obstructive pulmonary disease (COPD) and phenotypic features of asthma (bronchodilator reversibility and elevated blood eosinophils), but no asthma diagnosis, for whom treatment guidelines are limited.

Patients and methods: KRONOS (NCT02497001) and ETHOS (NCT02465567) enrolled patients with moderate-to-very-severe COPD, no current asthma diagnosis, and either ≥0 (KRONOS) or ≥1 (ETHOS) moderate/severe exacerbations in the prior year. This pooled post hoc analysis evaluated trough forced expiratory volume in 1 second (FEV1) and FEV1 area under the curve from hours 0 to 4 (AUC0-4) change from baseline over 12-24 weeks, moderate/severe exacerbation rates, and St George's Respiratory Questionnaire (SGRQ) total score over 24 weeks with ICS/LAMA/LABA (BGF 320/14.4/10 µg), LAMA/LABA (glycopyrronium/formoterol fumarate dihydrate [GFF] 14.4/10 µg), and ICS/LABA (budesonide/formoterol fumarate dihydrate [BFF] 320/10 µg) in patients with phenotypic features of asthma defined as reversibility to salbutamol and blood eosinophils ≥300 cells/mm3. Analyses were not adjusted for multiplicity.

Results: BGF improved trough FEV1 and FEV1 AUC0-4 versus GFF (least squares mean [LSM] difference [95% confidence interval (CI)] 125 [39-211] and 153 [59-247] mL) and BFF (LSM difference [95% CI] 118 [30-207] and 146 [49-243] mL). Exacerbation rates were estimated to be lower with BGF versus GFF and BFF (respective rate ratios [95% CI] 0.28 [0.19-0.43] and 0.69 [0.45-1.05]) and SGRQ total score was estimated to be improved with BGF versus GFF and BFF (respective LSM differences [95% CI] -5.18 [-8.11 to -2.24] and -1.09 [-4.08 to 1.91]).

Conclusion: BGF was estimated to have benefits on lung function, exacerbations, and health-related quality of life versus dual therapies in patients with COPD and phenotypic features of asthma.

Trial registration: ClinicalTrials.gov NCT02497001 and NCT02465567.

Keywords: COPD; asthma; budesonide/glycopyrronium/formoterol fumarate dihydrate; exacerbation; health-related quality of life; lung function.

PubMed Disclaimer

Conflict of interest statement

SM has received lecture fees from AstraZeneca, GlaxoSmithKline, KYORIN Pharmaceutical, Nippon Boehringer Ingelheim, and Novartis Pharma. MS is an employee of AstraZeneca K.K. and holds stock and/or stock options in the company. JRH reports grants from AstraZeneca, consulting fees from AstraZeneca; speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, and Takeda; travel support from AstraZeneca; and receipt of equipment from Nonin. DP, JM, KB, PFD, AM, and MP are employees of AstraZeneca and hold stock and/or stock options in the company. EAD is a former employee of AstraZeneca and held stock and/or stock options in the company.

Figures

Figure 1
Figure 1
Change from baseline in lung function over weeks 12–24 in patients with COPD and phenotypic features of asthma, apooled KRONOS and ETHOS mITT populations (n = 412).
Figure 2
Figure 2
Moderate/severe exacerbation rates over 24 weeks in patients with COPD and phenotypic features of asthma, apooled KRONOS and ETHOS mITT populations (n = 412).
Figure 3
Figure 3
Change in SGRQ total score over 24 weeks in patients with COPD and phenotypic features of asthma, apooled KRONOS and ETHOS mITT populations (n = 412).
See this image and copyright information in PMC

References

    1. Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J. 2019;54(3):1900561. doi:10.1183/13993003.00561-2019 - DOI - PubMed
    1. Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14(1):112. doi:10.1186/1471-2466-14-112 - DOI - PMC - PubMed
    1. Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971. doi:10.1183/09031936.06.00072105 - DOI - PubMed
    1. Pizzichini E, Pizzichini MMM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5):1511–1517. doi:10.1164/ajrccm.158.5.9804028 - DOI - PubMed
    1. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.00162414 - DOI - PubMed

Publication types

MeSH terms

Associated data